ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0882

Efficacy and Safety of Secukinumab in Patients with Spondyloarthritis and Enthesitis at the Achilles Tendon: 52-weeks Results from a Randomized, Placebo-controlled Phase 3b Trial

Frank Behrens1, Philipp Sewerin2, Eugenio De Miguel3, Yusuf Patel4, Anastas Batalov5, Eva Dokoupilova6, Christine Kleinmond7, Effie Pournara8, Ankita Shekhawat9, Claudia Jentzsch10, Annette Wiedon11 and Xenofon Baraliakos12, 1CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, 2Department of Rheumatology & Hiller Research Unit, University Hospital Düsseldorf, Duesseldorf, Germany, 3Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, 4Hull University Teaching Hospitals, Hull East Yorkshire, United Kingdom, 5Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, 6MEDICAL PLUS s.r.o., Uherske Hradiste, University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, Uherské Hradiště, Czech Republic, 7ClinProject GmbH, Eurasburg, Germany, 8Novartis Pharma AG, Basel, Switzerland, 9Novartis Healthcare Private Limited, Hyderabad, Telangana, India, 10Novartis Pharma GmbH, Nuremberg, Germany, 11Novartis Pharma GmbH, Nurnberg, Germany, 12Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany

Meeting: ACR Convergence 2020

Keywords: Biologicals, Imaging, Interleukins, Psoriatic arthritis, spondyloarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Enthesitis is a key feature of all types of spondyloarthritis (SpA) that substantially contributes to the overall burden of disease. Inhibition of the key effector cytokines of enthesitis, IL‑17, IL‑23, and TNF, has proved effective in resolution of PsA and axial (ax)SpA.1 Secukinumab (SEC) is a fully human monoclonal antibody that directly inhibits IL-17A and significantly reduces entheseal inflammation in patients (pts) with PsA.2 The clinical efficacy and safety outcomes from the ACHILLES trial in a heterogeneous SpA population (PsA and axSpA pts) with enthesitis at the Achilles tendon treated with SEC are presented.

Methods: ACHILLES study included pts (≥18 years) with a diagnosis of active PsA (CASPAR criteria and ≥1 TJC and SJC) or axSpA (ASAS axSpA criteria and total BASDAI ≥4) and MRI-positive heel enthesitis (according to the investigator’s judgement) refractory to standard treatment. Pts were randomized to receive s.c. SEC 150 mg, 300 mg or placebo (PBO) at baseline, Weeks (Wks) 1, 2, 3 and 4, followed by once every 4 wks. At Wk 24, pts on PBO were switched to SEC 150 or 300 mg. The primary endpoint was the proportion of pts achieving resolution of Achilles tendon enthesitis at the affected foot (assessed by the respective subcomponent of Leeds Enthesitis Index, LEI) with SEC vs PBO at Wk 24. Assessments at Wks 24 and 52 included LEI, heel pain (by NRS [0-10]), physician’s and pt’s heel enthesopathy activity and global assessment of disease activities (by VAS [0–100]), and quality of life (QoL, SF-36 v2). Analysis comparing treatments with respect to the primary efficacy variable used a logistic regression model and continuous variables were analyzed using an Analysis of covariance model. Missing values were handled using mixed-effects model repeated measures and last observation carry forward method.

Results: A total of 204 pts (128 PsA, 76 axSpA) were included (SEC, N=102; PBO, N=102; Table 1). A numerically higher percentage of SEC-treated pts, though not statistically significant vs PBO, reported resolution of Achilles tendon enthesitis at the affected foot (42.2% vs 31.4%) and in LEI (33.3% vs 23.5%) at Wk 24 (Table 2); statistically significant LEI improvement was achieved in PsA pts treated with SEC vs PBO (35.9% vs 18.8%, p=0.025). Pts with a BMI < 30 kg/m2 improved considerably with SEC vs PBO (49.2% vs 24.6%). Heel pain significantly improved in SEC-treated pts vs PBO (Table 2). Significant improvements in physician and pt reported heel enthesopathy activity along with physician and pt global assessment of disease activity were observed in SEC-treated pts vs PBO. SEC provided sustained improvements in all efficacy endpoints through Wk 52. The safety profile of SEC was consistent with previous studies.

Conclusion: Although SEC was not significantly superior to PBO in the resolution of Achilles tendon enthesitis as assessed by the LEI subcomponent at the affected foot, it significantly improved the burden of heel enthesitis, global disease activity, and QoL in pts with active SpA refractory to standard treatment.

References:

  1. Schett G, et al. Nat Rev Rheumatol. 2017;13:731–741.
  2. Coates LC, et al. Arthritis Res Ther. 2019;21:266.

Table 1: Demographics and Baseline Characteristics

Table 2: Clinical Efficacy Endpoints up to Week 52


Disclosure: F. Behrens, AbbVie, 2, 5, 8, Pfizer, 2, 5, 8, Roche, 2, 5, 8, Chugai, 2, 5, 8, Janssen, 2, 5, 8, Novartis, 2, 5, 8, UCB, 5, 8, BMS, 5, 8, Celgene, 5, 8, MSD, 5, 8, Biotest, 5, 8, Sanofi, 5, 8, Genzyme, 5, 8, Lilly, 5, 8, Boehringer, 5, 8, Galapagos, 5, 8; P. Sewerin, AbbVie, 2, 5, 8, Celgene, 2, 5, 8, Chugai, 2, 5, 8, Janssen-Cilag, 2, 8, Lilly, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, UCB, 2, 5, 8, Biogen, 5, 8, BMS, 5, 8, Hexal, 5, 8, Roche, 5, 8, Sanofi-Genzyme, 5, 8, Swedish Orphan Biovitrum, 5, 8; E. De Miguel, AbbVie, 2, 5, 8, BMS, 8, MSD, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Roche, 8, UCB, 8; Y. Patel, None; A. Batalov, AbbVie, 5, Amgen, 5, MSD, 5, Myland, 5, Novartis, 5, Pfizer, 5, Roche, 5, Sandoz, 5, UCB, 5; E. Dokoupilova, Samsung Bioepis, 2; C. Kleinmond, Novartis, 5; E. Pournara, Novartis, 1, 3; A. Shekhawat, Novartis, 3; C. Jentzsch, Novartis, 3; A. Wiedon, Novartis, 3; X. Baraliakos, AbbVie, 2, 5, Celgene, 2, 5, Galapagos, 2, 5, Janssen, 2, 5, Eli Lilly, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, UCB, 2, 5, Bristol-Myers Squibb, 2, 5, Chugai, 2, 5, MSD, 2, 5, Sandoz, 2, 5, Hexal, 2, 5.

To cite this abstract in AMA style:

Behrens F, Sewerin P, De Miguel E, Patel Y, Batalov A, Dokoupilova E, Kleinmond C, Pournara E, Shekhawat A, Jentzsch C, Wiedon A, Baraliakos X. Efficacy and Safety of Secukinumab in Patients with Spondyloarthritis and Enthesitis at the Achilles Tendon: 52-weeks Results from a Randomized, Placebo-controlled Phase 3b Trial [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/efficacy-and-safety-of-secukinumab-in-patients-with-spondyloarthritis-and-enthesitis-at-the-achilles-tendon-52-weeks-results-from-a-randomized-placebo-controlled-phase-3b-trial/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-secukinumab-in-patients-with-spondyloarthritis-and-enthesitis-at-the-achilles-tendon-52-weeks-results-from-a-randomized-placebo-controlled-phase-3b-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology